Ad blocking detected

Thank you for visiting CanadianInsider.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). Private browsing Firefox users should be able to disable tracking protection while visiting our website. Visit Mozilla support for more information. If you do not believe you have any ad-blocking software on your browser, you may want to try another browser, computer or internet service provider. Alternatively, you may consider the following if you want an ad-free experience.

Canadian Insider Club
$299/ year*
Daily Morning INK newsletter
+3 months archive
Canadian Market INK weekly newsletter
+3 months archive
30 publication downloads per month from the PDF store
Top 20 Gold, Top 30 Energy, Top 40 Stock downloads from the PDF store
All benefits of basic registration
No 3rd party display ads
JOIN THE CLUB

* Price is subject to applicable taxes.

Paid subscriptions and memberships are auto-renewing unless cancelled (easily done via the Account Settings Membership Status page after logging in). Once cancelled, a subscription or membership will terminate at the end of the current term.

Knight Therapeutics Inc. (T:GUD)

Business Focus: N/A

INK Edge Outlook

Insider Chart - Past 6 Months

INK Ultra Money Free

Insider Filings

Latest 10 SEDI filings for GUD within the last 6 months
Loading...
See all filings within the past 6 months

Company News

Feb 11, 2020 17:00 ET
Quebec, New Brunswick, Newfoundland, Nova Scotia and Manitoba join Alberta, Saskatchewan, in adding Knight’s PROBUPHINE® to their provincial drug plans in the fight against the opioid crisis
Knight Therapeutics Inc. (TSX:GUD) ("Knight"), a leading pan-American (ex-USA) specialty pharmaceutical company, announced today that PROBUPHINE®, the first and only subdermal implant approved in Canada, is now additionally publicly funded in...
Read full article
Jan 08, 2020 08:00 ET
Knight Partners with Debiopharm for the Commercialization of Trelstar® in Canada
Knight Therapeutics Inc., (TSX: GUD) (“Knight”) a pan-American (ex-USA) specialty pharmaceutical company and Debiopharm , a swiss-based, global biopharmaceutical company, today announced that they have entered into an exclusive agreement that...
Read full article
See more news stories

Valuation Ratios

Industry
Sector
Beta
0.73
--
--
Price to Sales - TTM
66.58
--
--
Price to Book - most recent quarter
0.98
--
--
Price to Cash Flow per share - TTM
39.91
--
--
Price to Free Cash Flow per share - TTM
--
--
--
See all valuations

Short Report

DateNumber of Shares ShortedNet Change
Feb 15, 20203,829,77264,806
Jan 31, 20203,764,966-178,781
Jan 15, 20203,943,74784,808
See Short Report

Business Summary

Sector:  N/A Industry:  N/A

See business summary

Twitter

Search (past week) for $GUD.CA

  • No tweets found